Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer

BACKGROUND: Stereotactic ablative radiotherapy (SABR) can achieve excellent local control rates in early-stage non-small cell lung cancer (NSCLC) and has emerged as a standard treatment option for patients who cannot undergo surgery or those with isolated recurrences. However, factors that may predi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Joe Y, Liu, Hui, Balter, Peter, Komaki, Ritsuko, Liao, Zhongxing, Welsh, James, Mehran, Reza J, Roth, Jack A, Swisher, Stephen G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444889/
https://www.ncbi.nlm.nih.gov/pubmed/22963661
http://dx.doi.org/10.1186/1748-717X-7-152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444889/
https://www.ncbi.nlm.nih.gov/pubmed/22963661
http://dx.doi.org/10.1186/1748-717X-7-152

Ejemplares similares